Resistance to PD-1 blockade immunotherapy is often associated with insufficient tumor antigenicity, constitutive PD-L1 expression, defects in IFN signal transduction within cancer cells and alterations in the regulation of oncogenic pathways (Escors, 2014; Sharma et al., 2017). Here, PDCD1 is linked to cancer.